Hyperacidity, GERD, and ulcers:
Indications for Dicyclomine HCl Syrup:
Irritable bowel syndrome.
Initially 20mg 4 times daily; after 1 week may increase to 40mg 4 times daily if tolerated. Discontinue if not effective within 2 weeks or daily doses ≥80mg are not tolerated.
<6months: see Contraindications. ≥6months: consult manufacturer.
Glaucoma. Unstable cardiovascular status. GI or urinary tract obstruction. Severe ulcerative colitis. Myasthenia gravis. Reflux esophagitis. Children <6months of age. Nursing mothers.
Inj: avoid IV administration (may cause thrombosis, inj site reactions). Autonomic neuropathy. Hepatic or renal impairment. Cardiovascular disease. Hypertension. Hyperthyroidism. Salmonella dysentery. Toxic megacolon. Ulcerative colitis. GI or GU obstruction. High environmental temperature. Diarrhea. Elderly. Debilitated. Pregnancy (Cat.B).
Antacids may inhibit absorption; avoid. May antagonize anti-glaucoma agents or drugs that alter GI motility (eg, metoclopramide). Antagonized by agents used to treat achlorhydria and those used to test gastric secretion. Additive anticholinergic effects with other anticholinergics, narcotic analgesics, type I antiarrhythmics, antihistamines, antipsychotics, tricyclics, amantadine, benzodiazepines, MAOIs, nitrites, nitrates, sympathomimetics. May affect absorption of sust rel dosage forms.
Dizziness, dry mouth, blurred vision, nausea, somnolence, asthenia, and nervousness; cardiovascular and CNS symptoms (eg, psychosis, delirium). Fatal reactions have occurred in infants.
Caps, tabs—100; Syrup—contact supplier; Amps (2mL)—5